TXG
10x Genomics, Inc.
Price Chart
Latest Quote
$32.13
+0.38 (+1.20%)
Current Price
| Previous Close | $31.75 |
| Open | $31.47 |
| Day High | $33.61 |
| Day Low | $31.27 |
| Volume | 4,417,951 |
Stock Information
| Shares Outstanding | 116.88M |
| Total Debt | $81.39M |
| Cash Equivalents | $539.85M |
| Revenue | $638.78M |
| Net Income | $-22.66M |
| Sector | Healthcare |
| Industry | Health Information Services |
| Market Cap | $4.08B |
| EPS (TTM) | $-0.17 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.57B |
| Sales | $638.78M |
| Income | $-22.66M |
| Book/sh | $6.24 |
| Cash/sh | $4.62 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 5.25 |
| Current Ratio | 5.90 |
| Debt/Eq | 9.99 |
Returns & Margins
| ROA | -4.48% |
| ROE | -2.98% |
| Gross Margin | 69.68% |
| Operating Margin | -11.30% |
| Profit Margin | -3.55% |
Ownership
| Insider Ownership | 1.66% |
| Institutional Ownership | 113.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 160.65 |
| P/S | 6.39 |
| P/B | 5.15 |
Analyst Data
| Recommendation | buy |
| Target Price | $25.77 |
Technical Indicators
| SMA20 | $28.93 |
| SMA50 | $25.09 |
| SMA200 | $18.99 |
| RSI | 62.02 |
| ATR | 2.4077 |
| Shares Float | 114.78M |
| Short Float | 19.29% |
| Short Ratio | 5.67 |
| Volatility | 2.11 |
| Rel Volume | 1.41 |
Performance History
| Week | +10.37% |
| Month | +49.79% |
| Quarter | +85.19% |
| 6 Months | +103.87% |
| YTD | +93.32% |
| Year | +191.83% |
| 3 Years | -42.47% |
| 5 Years | -83.19% |
| 10 Years | -39.09% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $32.13 | 4,723,300 |
| 2026-06-16 | $31.75 | 2,962,000 |
| 2026-06-15 | $32.22 | 4,479,400 |
| 2026-06-12 | $28.84 | 2,005,700 |
| 2026-06-11 | $29.05 | 2,960,500 |
| 2026-06-10 | $29.11 | 3,252,300 |
| 2026-06-09 | $30.59 | 3,285,900 |
| 2026-06-08 | $29.18 | 3,106,700 |
| 2026-06-05 | $31.04 | 3,801,700 |
| 2026-06-04 | $33.50 | 4,152,200 |
| 2026-06-03 | $32.16 | 3,380,700 |
| 2026-06-02 | $30.71 | 3,094,900 |
| 2026-06-01 | $29.59 | 3,026,400 |
| 2026-05-29 | $28.31 | 2,915,100 |
| 2026-05-28 | $27.99 | 3,457,900 |
| 2026-05-27 | $25.51 | 3,569,000 |
| 2026-05-26 | $24.62 | 1,970,300 |
| 2026-05-22 | $23.68 | 3,797,800 |
| 2026-05-21 | $24.68 | 4,060,600 |
| 2026-05-20 | $23.98 | 2,926,200 |
| 2026-05-19 | $22.29 | 2,321,000 |
| 2026-05-18 | $21.45 | 2,653,200 |
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
đ° Latest News
Cathie Wood Cleans House: Another Day Of Heavy Sales
Investor's Business Daily âĸ 2026-06-16T13:10:58Z
X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake
Insider Monkey âĸ 2026-06-16T02:34:59Z
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
GuruFocus.com âĸ 2026-06-15T18:48:08Z3 Small-Cap Stocks with Questionable Fundamentals
StockStory âĸ 2026-06-11T12:09:37Z
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
Zacks âĸ 2026-06-10T17:04:00Z
Is It Too Late To Consider 10x Genomics (TXG) After Its Recent 187% Surge?
Simply Wall St. âĸ 2026-06-10T07:14:20Z
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
Motley Fool âĸ 2026-06-01T06:23:09Z
The 5 Most Interesting Analyst Questions From 10x Genomicsâs Q1 Earnings Call
StockStory âĸ 2026-05-18T17:00:55Z
1 Cash-Producing Stock on Our Watchlist and 2 We Question
StockStory âĸ 2026-05-13T21:40:55Z
Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?
Simply Wall St. âĸ 2026-05-13T05:18:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $198,942,000 | $196,303,000 | $209,414,000 | $120,386,000 |
| Cost Of Revenue | $198,942,000 | $196,303,000 | $209,414,000 | $120,386,000 |
| Total Revenue | $642,823,000 | $610,785,000 | $618,727,000 | $516,409,000 |
| Operating Revenue | $642,823,000 | $610,785,000 | $618,727,000 | $516,409,000 |
| Expenses | ||||
| Interest Expense | $0 | $4,000 | $33,000 | $476,000 |
| Total Expenses | $753,708,000 | $805,344,000 | $823,076,000 | $684,353,000 |
| Other Income Expense | $50,930,000 | $-2,067,000 | $-61,266,000 | $-198,000 |
| Other Non Operating Income Expenses | $1,030,000 | $-2,067,000 | $-286,000 | $-198,000 |
| Net Non Operating Interest Income Expense | $20,048,000 | $18,926,000 | $16,852,000 | $6,171,000 |
| Interest Expense Non Operating | $0 | $4,000 | $33,000 | $476,000 |
| Operating Expense | $554,766,000 | $609,041,000 | $613,662,000 | $563,967,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Net Interest Income | $20,048,000 | $18,926,000 | $16,852,000 | $6,171,000 |
| Interest Income | $20,048,000 | $18,930,000 | $16,885,000 | $6,647,000 |
| Normalized Income | $-82,965,000 | $-182,627,000 | $-206,924,800 | $-166,000,000 |
| Net Income From Continuing And Discontinued Operation | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Total Operating Income As Reported | $-60,985,000 | $-194,559,000 | $-265,329,000 | $-167,944,000 |
| Net Income Common Stockholders | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Net Income | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Net Income Including Noncontrolling Interests | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Net Income Continuous Operations | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Pretax Income | $-39,907,000 | $-177,700,000 | $-248,763,000 | $-161,971,000 |
| Special Income Charges | $49,900,000 | $0 | $-60,980,000 | $0 |
| Interest Income Non Operating | $20,048,000 | $18,930,000 | $16,885,000 | $6,647,000 |
| Operating Income | $-110,885,000 | $-194,559,000 | $-204,349,000 | $-167,944,000 |
| Gross Profit | $443,881,000 | $414,482,000 | $409,313,000 | $396,023,000 |
| Per Share | ||||
| Diluted EPS | $-0.35 | $-1.52 | $-2.18 | $-1.46 |
| Basic EPS | $-0.35 | $-1.52 | $-2.18 | $-1.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $10,479,000 | $0 | $-12,805,800 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-45,991,000 | $-133,988,000 | $-144,131,000 | $-128,489,000 |
| Total Unusual Items | $49,900,000 | $0 | $-60,980,000 | $0 |
| Total Unusual Items Excluding Goodwill | $49,900,000 | $0 | $-60,980,000 | $0 |
| Reconciled Depreciation | $43,816,000 | $43,708,000 | $43,619,000 | $33,006,000 |
| EBITDA (Bullshit earnings) | $3,909,000 | $-133,988,000 | $-205,111,000 | $-128,489,000 |
| EBIT | $-39,907,000 | $-177,696,000 | $-248,730,000 | $-161,495,000 |
| Diluted Average Shares | $124,749,885 | $120,451,550 | $117,165,036 | $113,858,684 |
| Basic Average Shares | $124,749,885 | $120,451,550 | $117,165,036 | $113,858,684 |
| Diluted NI Availto Com Stockholders | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Tax Provision | $3,637,000 | $4,927,000 | $6,336,000 | $4,029,000 |
| Other Special Charges | $-49,900,000 | - | $60,980,000 | - |
| Research And Development | $238,632,000 | $264,698,000 | $270,332,000 | $265,667,000 |
| Selling General And Administration | $316,134,000 | $344,343,000 | $343,330,000 | $298,300,000 |
| Restructuring And Mergern Acquisition | - | - | $0 | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $729,486,000 | $689,952,000 | $719,916,000 | $778,374,000 |
| Total Assets | $1,041,365,000 | $918,636,000 | $965,143,000 | $1,028,980,000 |
| Total Non Current Assets | $356,914,000 | $334,249,000 | $369,121,000 | $393,945,000 |
| Other Non Current Assets | $2,913,000 | $4,129,000 | $3,062,000 | $7,366,000 |
| Goodwill And Other Intangible Assets | $66,840,000 | $20,182,000 | $21,127,000 | $27,369,000 |
| Other Intangible Assets | $62,329,000 | $15,671,000 | $16,616,000 | $22,858,000 |
| Current Assets | $684,451,000 | $584,387,000 | $596,022,000 | $635,035,000 |
| Other Current Assets | $22,208,000 | $19,410,000 | $18,789,000 | $16,578,000 |
| Inventory | $56,341,000 | $83,107,000 | $73,706,000 | $81,629,000 |
| Receivables | $82,493,000 | $88,468,000 | $114,832,000 | $104,211,000 |
| Other Receivables | $35,480,000 | $606,000 | - | - |
| Accounts Receivable | $47,013,000 | $87,862,000 | $114,832,000 | $104,211,000 |
| Cash Cash Equivalents And Short Term Investments | $523,409,000 | $393,402,000 | $388,695,000 | $429,984,000 |
| Cash And Cash Equivalents | $473,966,000 | $344,067,000 | $359,284,000 | $219,746,000 |
| Restricted Cash | - | - | $0 | $2,633,000 |
| Allowance For Doubtful Accounts Receivable | - | - | $-100,000 | $-100,000 |
| Gross Accounts Receivable | - | - | $114,932,000 | $104,311,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $84,361,000 | $82,613,000 | $95,370,000 | $95,176,000 |
| Long Term Debt And Capital Lease Obligation | $73,376,000 | $73,327,000 | $83,849,000 | $86,139,000 |
| Current Debt And Capital Lease Obligation | $10,985,000 | $9,286,000 | $11,521,000 | $9,037,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $245,039,000 | $208,502,000 | $224,100,000 | $223,237,000 |
| Total Non Current Liabilities Net Minority Interest | $91,585,000 | $90,869,000 | $96,938,000 | $92,280,000 |
| Other Non Current Liabilities | $7,708,000 | $5,029,000 | $4,275,000 | $2,976,000 |
| Non Current Deferred Liabilities | $10,501,000 | $12,513,000 | $8,814,000 | $3,165,000 |
| Current Liabilities | $153,454,000 | $117,633,000 | $127,162,000 | $130,957,000 |
| Other Current Liabilities | $41,062,000 | $14,126,000 | $12,529,000 | $9,730,000 |
| Current Deferred Liabilities | $23,902,000 | $20,658,000 | $13,150,000 | $7,867,000 |
| Payables And Accrued Expenses | $45,304,000 | $48,856,000 | $68,529,000 | $84,313,000 |
| Payables | $25,494,000 | $20,847,000 | $20,787,000 | $25,678,000 |
| Other Payable | $5,542,000 | $3,002,000 | - | - |
| Total Tax Payable | $7,219,000 | $4,936,000 | $5,049,000 | $4,079,000 |
| Accounts Payable | $12,733,000 | $12,909,000 | $15,738,000 | $21,599,000 |
| Equity | ||||
| Common Stock Equity | $796,326,000 | $710,134,000 | $741,043,000 | $805,743,000 |
| Total Equity Gross Minority Interest | $796,326,000 | $710,134,000 | $741,043,000 | $805,743,000 |
| Stockholders Equity | $796,326,000 | $710,134,000 | $741,043,000 | $805,743,000 |
| Gains Losses Not Affecting Retained Earnings | $225,000 | $-493,000 | $-429,000 | $-4,335,000 |
| Other Equity Adjustments | $225,000 | $-493,000 | $-429,000 | $-4,335,000 |
| Retained Earnings | $-1,510,591,000 | $-1,467,047,000 | $-1,284,420,000 | $-1,029,321,000 |
| Other | ||||
| Ordinary Shares Number | $127,691,329 | $122,291,837 | $119,095,362 | $115,195,009 |
| Share Issued | $127,691,329 | $122,291,837 | $119,095,362 | $115,195,009 |
| Tangible Book Value | $729,486,000 | $689,952,000 | $719,916,000 | $778,374,000 |
| Invested Capital | $796,326,000 | $710,134,000 | $741,043,000 | $805,743,000 |
| Working Capital | $530,997,000 | $466,754,000 | $468,860,000 | $504,078,000 |
| Capital Lease Obligations | $84,361,000 | $82,613,000 | $95,370,000 | $95,176,000 |
| Total Capitalization | $796,326,000 | $710,134,000 | $741,043,000 | $805,743,000 |
| Additional Paid In Capital | $2,306,690,000 | $2,177,672,000 | $2,025,890,000 | $1,839,397,000 |
| Capital Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Common Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $10,501,000 | $12,513,000 | $8,814,000 | $3,165,000 |
| Long Term Capital Lease Obligation | $73,376,000 | $73,327,000 | $83,849,000 | $86,139,000 |
| Current Deferred Revenue | $23,902,000 | $20,658,000 | $13,150,000 | $7,867,000 |
| Current Capital Lease Obligation | $10,985,000 | $9,286,000 | $11,521,000 | $9,037,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $32,201,000 | $24,707,000 | $21,433,000 | $20,010,000 |
| Current Accrued Expenses | $19,810,000 | $28,009,000 | $47,742,000 | $58,635,000 |
| Goodwill | $4,511,000 | $4,511,000 | $4,511,000 | $4,511,000 |
| Net PPE | $287,161,000 | $309,938,000 | $344,932,000 | $359,210,000 |
| Accumulated Depreciation | $-153,464,000 | $-122,967,000 | $-103,491,000 | $-68,830,000 |
| Gross PPE | $440,625,000 | $432,905,000 | $448,423,000 | $428,040,000 |
| Leases | $89,724,000 | $89,567,000 | $96,405,000 | $91,518,000 |
| Construction In Progress | $2,929,000 | $5,152,000 | $7,252,000 | $152,995,000 |
| Other Properties | $60,450,000 | $57,290,000 | $65,361,000 | $69,882,000 |
| Machinery Furniture Equipment | $103,264,000 | $97,037,000 | $96,596,000 | $76,865,000 |
| Buildings And Improvements | $147,493,000 | $147,094,000 | $146,044,000 | $0 |
| Land And Improvements | $36,765,000 | $36,765,000 | $36,765,000 | $36,780,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $23,183,000 | $16,736,000 | $17,247,000 | $22,482,000 |
| Work In Process | $17,135,000 | $27,441,000 | $21,975,000 | $24,650,000 |
| Raw Materials | $16,023,000 | $38,930,000 | $34,484,000 | $34,497,000 |
| Other Short Term Investments | $49,443,000 | $49,335,000 | $29,411,000 | $210,238,000 |
| Non Current Accrued Expenses | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $130,115,000 | $-6,729,000 | $-64,721,000 | $-165,267,000 |
| Operating Activities | ||||
| Operating Cash Flow | $136,050,000 | $6,664,000 | $-15,197,000 | $-33,606,000 |
| Cash Flow From Continuing Operating Activities | $136,050,000 | $6,664,000 | $-15,197,000 | $-33,606,000 |
| Operating Gains Losses | - | $3,000 | $1,718,000 | $1,086,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,935,000 | $-13,393,000 | $-49,524,000 | $-131,661,000 |
| Investing Cash Flow | $-13,438,000 | $-32,631,000 | $133,492,000 | $-350,887,000 |
| Cash Flow From Continuing Investing Activities | $-13,438,000 | $-32,631,000 | $133,492,000 | $-350,887,000 |
| Net Other Investing Changes | $-9,268,000 | - | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $6,803,000 | $10,914,000 | $13,669,000 | $15,817,000 |
| Cash Flow From Continuing Financing Activities | $6,803,000 | $10,914,000 | $13,669,000 | $15,817,000 |
| Net Other Financing Charges | - | - | $-5,814,000 | $-5,409,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $436,000 | $841,000 |
| Income Tax Paid Supplemental Data | $2,391,000 | $5,641,000 | $4,927,000 | $3,925,000 |
| End Cash Position | $473,966,000 | $344,067,000 | $359,284,000 | $227,353,000 |
| Beginning Cash Position | $344,067,000 | $359,284,000 | $227,353,000 | $596,073,000 |
| Effect Of Exchange Rate Changes | $484,000 | $-164,000 | $-33,000 | $-44,000 |
| Changes In Cash | $129,415,000 | $-15,053,000 | $131,964,000 | $-368,676,000 |
| Proceeds From Stock Option Exercised | $6,803,000 | $10,914,000 | $19,483,000 | $21,226,000 |
| Net Investment Purchase And Sale | $1,765,000 | $-19,238,000 | $183,016,000 | $-215,226,000 |
| Sale Of Investment | $125,200,000 | $29,638,000 | $183,016,000 | $67,645,000 |
| Purchase Of Investment | $-123,435,000 | $-48,876,000 | $0 | $-282,871,000 |
| Net Intangibles Purchase And Sale | $0 | $-1,000,000 | $-923,000 | $0 |
| Purchase Of Intangibles | $0 | $-1,000,000 | $-923,000 | $0 |
| Net PPE Purchase And Sale | $-5,935,000 | $-12,393,000 | $-48,601,000 | $-131,661,000 |
| Purchase Of PPE | $-5,935,000 | $-12,393,000 | $-48,601,000 | $-131,661,000 |
| Change In Working Capital | $24,939,000 | $1,254,000 | $17,343,000 | $-39,417,000 |
| Change In Other Working Capital | $8,393,000 | $14,863,000 | $8,295,000 | $4,464,000 |
| Change In Other Current Liabilities | $-8,914,000 | $-11,708,000 | $-7,387,000 | $-9,365,000 |
| Change In Other Current Assets | $689,000 | $-1,084,000 | $-678,000 | $925,000 |
| Change In Payables And Accrued Expense | $-7,279,000 | $-16,090,000 | $22,284,000 | $9,194,000 |
| Change In Accrued Expense | $-5,153,000 | $-12,736,000 | $28,301,000 | $3,336,000 |
| Change In Payable | $-2,126,000 | $-3,354,000 | $-6,017,000 | $5,858,000 |
| Change In Account Payable | $-2,126,000 | $-3,354,000 | $-6,017,000 | $5,858,000 |
| Change In Prepaid Assets | $-2,343,000 | $-1,901,000 | $-2,429,000 | $-4,495,000 |
| Change In Inventory | $27,953,000 | $-9,777,000 | $7,871,000 | $-21,192,000 |
| Change In Receivables | $6,440,000 | $26,951,000 | $-10,613,000 | $-18,948,000 |
| Changes In Account Receivables | $41,314,000 | $26,951,000 | $-10,613,000 | $-18,948,000 |
| Other Non Cash Items | $-346,000 | $523,000 | $427,000 | $1,957,000 |
| Stock Based Compensation | $109,118,000 | $140,749,000 | $166,950,000 | $136,848,000 |
| Asset Impairment Charge | $2,067,000 | $3,054,000 | $9,845,000 | $0 |
| Depreciation Amortization Depletion | $43,816,000 | $43,708,000 | $43,619,000 | $33,006,000 |
| Depreciation And Amortization | $43,816,000 | $43,708,000 | $43,619,000 | $33,006,000 |
| Depreciation | $43,816,000 | $43,708,000 | $43,619,000 | $33,006,000 |
| Net Income From Continuing Operations | $-43,544,000 | $-182,627,000 | $-255,099,000 | $-166,000,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-4,000,000 |
| Purchase Of Business | - | $0 | $0 | $-4,000,000 |
| Gain Loss On Investment Securities | - | $3,000 | $1,718,000 | - |
| Amortization Of Securities | - | - | $427,000 | $871,000 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $1,086,000 |
Fetched: 2026-06-17